Seaport Therapeutics, Inc. Common Stock

SPTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$24.31

+$0.275 · +1.14%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

Company profile

Company website

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Daphne Zohar
Listed since: May 1, 2026
Employees: 58

Market position

Day range

Current $24.31

$23.78$24.995

52-week range

Current $24.31

$14.85$26.32

Open: $23.81
Previous close: $24.035
Volume: 83.15K; 0.25× average
Average volume: 326.79K; Average daily volume
Market cap: 1.3B USD
Beta: 1.13; Market reference 1
50-day average: $20.9846; +15.85% above average
200-day average: $19.5239; +24.51% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 725.78M USD
P/E (TTM): -14.73×
P/B (TTM): 3.08×
P/S (TTM): 0×
EV / EBITDA: -8.45×
Earnings yield: -9.77%
Free cash flow yield: -10.21%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 80.91%
Return on assets: -30.07%
Return on invested capital: -36.70%

Financial health

Debt / equity: 0.01×
Current ratio: 17.46×

Financial statements

Metric (USD)	FY2025
Research and development	66.31M USD
Selling, general, and administrative	20.98M USD
Operating expenses	87.29M USD
Interest income	11.4M USD
Depreciation and amortization	1.41M USD
Operating income	−87.29M USD
Net income	−74.88M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 0%; 0 beats, 1 miss, 0 met estimates
Average EPS surprise: -186.92%; 1 comparable report
Latest EPS result: -1.78; Estimate -0.62 · Miss by 186.92%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$43.33

78.24% upside

Past 12 months12-month forecastHigh $50.00Average $43.33Low $30.00

Recent analyst actions

1 institution

SPTX news

247wallst.comAug 20, 2026

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those…

Read source

defenseworld.netAug 18, 2026

Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High – Here’s What Happened

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $25.07 and last traded at $24.40, with a volume of 98612 shares.…

Read source

seekingalpha.comAug 11, 2026

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in…

Read source

gurufocus.comAug 3, 2026

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

[url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (âSeaportâ or the âCompanyâ), a clinical-stage therapeutics company that is inventing and develo

Read source

businesswire.comAug 3, 2026

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

Read source

gurufocus.comJun 9, 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tra

Read source